IL272798B2 - חומרים אגוניסטים קושרי קולטן tnf - Google Patents
חומרים אגוניסטים קושרי קולטן tnfInfo
- Publication number
- IL272798B2 IL272798B2 IL272798A IL27279820A IL272798B2 IL 272798 B2 IL272798 B2 IL 272798B2 IL 272798 A IL272798 A IL 272798A IL 27279820 A IL27279820 A IL 27279820A IL 272798 B2 IL272798 B2 IL 272798B2
- Authority
- IL
- Israel
- Prior art keywords
- seq
- amino acid
- acid sequence
- heavy chain
- light chain
- Prior art date
Links
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 title 1
- 230000001270 agonistic effect Effects 0.000 title 1
- 239000011230 binding agent Substances 0.000 title 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 32
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 3
- 102000003390 tumor necrosis factor Human genes 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15050255 | 2015-01-08 | ||
| PCT/EP2016/050308 WO2016110584A1 (en) | 2015-01-08 | 2016-01-08 | Agonistic tnf receptor binding agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL272798A IL272798A (he) | 2020-04-30 |
| IL272798B1 IL272798B1 (he) | 2024-01-01 |
| IL272798B2 true IL272798B2 (he) | 2024-05-01 |
Family
ID=62452825
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309430A IL309430A (he) | 2015-01-08 | 2016-01-08 | חומרים אגוניסטים קושרי קולטן tnf |
| IL272798A IL272798B2 (he) | 2015-01-08 | 2016-01-08 | חומרים אגוניסטים קושרי קולטן tnf |
| IL252669A IL252669B (he) | 2015-01-08 | 2017-06-05 | חומרים אגוניסטים קושרי קולטן tnf |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309430A IL309430A (he) | 2015-01-08 | 2016-01-08 | חומרים אגוניסטים קושרי קולטן tnf |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL252669A IL252669B (he) | 2015-01-08 | 2017-06-05 | חומרים אגוניסטים קושרי קולטן tnf |
Country Status (1)
| Country | Link |
|---|---|
| IL (3) | IL309430A (he) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008051424A2 (en) * | 2006-10-20 | 2008-05-02 | University Of Southampton | Human immune therapies using a cd27 agonist alone or in combination with other immune modulators |
| WO2009034172A1 (en) * | 2007-09-14 | 2009-03-19 | Vrije Universiteit Brussel | Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination |
-
2016
- 2016-01-08 IL IL309430A patent/IL309430A/he unknown
- 2016-01-08 IL IL272798A patent/IL272798B2/he unknown
-
2017
- 2017-06-05 IL IL252669A patent/IL252669B/he active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008051424A2 (en) * | 2006-10-20 | 2008-05-02 | University Of Southampton | Human immune therapies using a cd27 agonist alone or in combination with other immune modulators |
| WO2009034172A1 (en) * | 2007-09-14 | 2009-03-19 | Vrije Universiteit Brussel | Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination |
Non-Patent Citations (2)
| Title |
|---|
| HIRANO TESTUO ET AL., " CD27 SYNERGIZES WITH CD40 TO INDUCE IGM, IGG AND IGA ANTIBODY RESPONSES OF PERIPHERAL BLOOD B CELLS IN THE PRESENCE OF IL-2 AND IL-10", 31 October 2003 (2003-10-31) * |
| WESTWOOD JENNIFER A ET AL., " COMBINATION ANTI-CD137 AND ANTI-CD40 ANTIBODY THERAPY IN MURINE MYC-DRIVEN HEMATOLOGICAL CANCERS", 2 June 2014 (2014-06-02) * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL272798A (he) | 2020-04-30 |
| IL272798B1 (he) | 2024-01-01 |
| IL252669B (he) | 2020-03-31 |
| IL252669A0 (he) | 2017-08-31 |
| IL309430A (he) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191824T1 (hr) | Agonistička sredstva za vezivanje tnf receptora | |
| RU2495050C2 (ru) | Связующий элемент для рецептора gm-csf | |
| HRP20180269T1 (hr) | Anti-cd40 protutijela, upotrebe i postupci | |
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| JP2018521691A5 (he) | ||
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| RU2018145852A (ru) | Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение | |
| JP2020528768A5 (he) | ||
| JP2019501883A5 (he) | ||
| JP2015535828A5 (he) | ||
| HRP20201432T1 (hr) | Il-17a sredstvo za vezivanje i njegove uporabe | |
| JP2013121353A5 (he) | ||
| HRP20140108T1 (hr) | Protutijela protiv sklerostina | |
| JP2013542194A5 (he) | ||
| RU2016138744A (ru) | Антитела, фармацевтические композиции и их применения | |
| IL269270B (he) | שיטה ותכשירים לטיפול חיסוני תאי | |
| JP2016519650A5 (he) | ||
| JP2016520595A5 (he) | ||
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| HRP20191277T1 (hr) | Anti-cd26 antitijela i njihove primjene | |
| RU2020127196A (ru) | Антитело против 4-1bb, его антигенсвязывающий фрагмент и его медицинское применение | |
| RU2019139093A (ru) | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение | |
| JP2018522562A5 (he) | ||
| JP2020537520A5 (he) | ||
| RU2017134043A (ru) | Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью |